Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma

References

• JohannessenCMJohnsonLAPiccioniFA melanocyte lineage program confers resistance to MAP kinase pathway inhibitionNature2013504747813814224185007
   PubMed Web of Science ®Google Scholar
• FlahertyKTPuzanovIKimKBInhibition of mutated, activated BRAF in metastatic melanomaN Engl J Med2010363980981920818844
   PubMed Web of Science ®Google Scholar
• DaviesHBignellGRCoxCMutations of the BRAF gene in human cancerNature2002417689294995412068308
   PubMed Web of Science ®Google Scholar
• PollockPMHarperULHansenKSHigh frequency of BRAF mutations in neviNat Genet2003331192012447372
   PubMed Web of Science ®Google Scholar
• WojnowskiLZimmerAMBeckTWEndothelial apoptosis in Braf-deficient miceNat Genet19971632932979207797
   PubMed Web of Science ®Google Scholar
• DibbNJDilworthSMMolCDSwitching on kinases: oncogenic activation of BRAF and the PDGFR familyNat Rev Cancer20044971872715343278
   PubMed Web of Science ®Google Scholar
• HartsoughEShaoYAplinAEResistance to RAF inhibitors revisitedJ Invest Dermatol2014134231932524108405
   PubMed Web of Science ®Google Scholar
• RibasAFlahertyKTBRAF targeted therapy changes the treatment paradigm in melanomaNat Rev Clin Oncol20118742643321606968
   PubMed Web of Science ®Google Scholar
• BollagGTsaiJZhangJVemurafenib: the first drug approved for BRAF-mutant cancerNat Rev Drug Discov2012111173886
   Web of Science ®Google Scholar
• MoritaHNagaiRVemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011365151448 author reply 145021995398
   PubMedGoogle Scholar
• ChapmanPBHauschildARobertCBRIM-3 Study GroupImproved survival with vemurafenib in melanoma with BRAF V600E mutationN Engl J Med2011364262507251621639808
   PubMed Web of Science ®Google Scholar
• SosmanJAKimKBSchuchterLSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenibN Engl J Med2012366870771422356324
   PubMed Web of Science ®Google Scholar
• HauschildAGrobJJDemidovLVDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialLancet2012380983935836522735384
   PubMed Web of Science ®Google Scholar
• FalchookGLongGKurzrockRRAF inhibitor dabrafenib (GSK2118436) is active in melanoma brain metastases, multiple BRAF genotypes and diverse cancersLancet20123799829189322608338
   PubMed Web of Science ®Google Scholar
• WeeraratnaATRAF around the edges – the paradox of BRAF inhibitorsN Engl J Med2012366327127322256810
   PubMed Web of Science ®Google Scholar
• MargolinKBRAF inhibition and beyond in advanced melanomaLancet2012380983932032222735383
   PubMed Web of Science ®Google Scholar
• SolitDBRosenNResistance to BRAF inhibition in melanomasN Engl J Med2011364877277421345109
   PubMed Web of Science ®Google Scholar
• GibneyGTSondakVKExtending the reach of BRAF-targeted cancer therapyLancet201237998291858185922608322
   PubMed Web of Science ®Google Scholar
• JohannessenCMBoehmJSKimSYCOT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature2010468732696897221107320
   PubMed Web of Science ®Google Scholar
• PoulikakosPIZhangCBollagGShokatKMRosenNRAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature2010464728742743020179705
   PubMed Web of Science ®Google Scholar
• PoulikakosPIPersaudYJanakiramanMRAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature2011480737738739022113612
   PubMed Web of Science ®Google Scholar
• CorcoranRBDias-SantagataDBergethonKIafrateAJSettlemanJEngelmanJABRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutationSci Signal20103149ra8421098728
   PubMed Web of Science ®Google Scholar
• NazarianRShiHWangQMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature2010468732697397721107323
   PubMed Web of Science ®Google Scholar
• HeidornSJMilagreCWhittakerSKinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAFCell2010140220922120141835
   PubMed Web of Science ®Google Scholar
• RajagopalanHBardelliALengauerCKinzlerKWVogelsteinBVelculescuVETumorigenesis: RAF/RAS oncogenes and mismatch-repair statusNature2002418690193412198537
   PubMed Web of Science ®Google Scholar
• XingFPersaudYPratilasCAConcurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAFOncogene201231444645721725359
   PubMed Web of Science ®Google Scholar
• BollagGHirthPTsaiJClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature2010467731559659920823850
   PubMed Web of Science ®Google Scholar
• CutlerREJrStephensRMSaracinoMRMorrisonDKAutoregulation of the Raf-1 serine/threonine kinaseProc Natl Acad Sci U S A19989516921492199689060
   PubMed Web of Science ®Google Scholar
• WanPTGarnettMJRoeSMCancer Genome ProjectMechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAFCell2004116685586715035987
   PubMed Web of Science ®Google Scholar
• HodisEWatsonIRKryukovGVA landscape of driver mutations in melanomaCell2012150225126322817889
   PubMed Web of Science ®Google Scholar
• PierottiMATamboriniENegriTPriclSPilottiSTargeted therapy in GIST: in silico modeling for prediction of resistanceNat Rev Clin Oncol20118316117021364689
   PubMed Web of Science ®Google Scholar
• WagleNEmeryCBergerMFDissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profilingJ Clin Oncol201129223085309621383288
   PubMed Web of Science ®Google Scholar
• TsaiJLeeJTWangWDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProc Natl Acad Sci U S A200810583041304618287029
   PubMed Web of Science ®Google Scholar
• TangH-CChenY-CMolecular insight and resolution for tumors harboring the H-ras (G12V) mutationRSC Adv20155272062320633
   Web of Science ®Google Scholar
• LinTYFanCWMaaMCLeuTHLipopolysaccharide-promoted proliferation of Caco-2 cells is mediated by c-Src induction and ERK activationBiomedicine (Taipei)201551525705585
   PubMedGoogle Scholar
• LiuSPHsuCYFuRHSambucus williamsii induced embryonic stem cells differentiated into neuronsBiomedicine (Taipei)201551325705583
   PubMedGoogle Scholar
• TangHCChenCYDrug design of cyclin-dependent kinase 2 inhibitor for melanoma from traditional Chinese medicineBiomed Res Int2014201479874225045703
   PubMed Web of Science ®Google Scholar
• ChenHXLaiCHHsuHYThe bacterial interactions in the nasopharynx of children receiving adenoidectomyBiomedicine (Taipei)201551625705586
   PubMedGoogle Scholar
• ChenCYTCM Database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening in silicoPLoS One201161e1593921253603
   PubMed Web of Science ®Google Scholar
• KongXQinJLiZDevelopment of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimizationOrg Biomol Chem201210367402741722875039
   PubMed Web of Science ®Google Scholar
• ParkHChoiHHongSIdentification of novel BRAF kinase inhibitors with structure-based virtual screeningBioorg Med Chem Lett201121195753575621873050
   PubMed Web of Science ®Google Scholar
• LuoCXiePMarmorsteinRIdentification of BRAF inhibitors through in silico screeningJ Med Chem200851196121612718783202
   PubMed Web of Science ®Google Scholar
• KingAJPatrickDRBatorskyRSDemonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885Cancer Res20066623111001110517145850
   PubMed Web of Science ®Google Scholar
• ChenCYWeighted equation and rules – a novel concept for evaluating protein-ligand interactionJ Biomol Struct Dyn200927327128219795911
   PubMed Web of Science ®Google Scholar
• MénardDNiculescu-DuvazIDijkstraHPNovel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ringJ Med Chem200952133881389119473026
   PubMed Web of Science ®Google Scholar
• ChenCYA novel integrated framework and improved methodology of computer-aided drug designCurr Top Med Chem201313996598823651478
   PubMed Web of Science ®Google Scholar
• PronkSPállSSchulzRGROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkitBioinformatics201329784585423407358
   PubMed Web of Science ®Google Scholar